Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2023 Earnings Call Transcript

Page 8 of 8

Charles Duncan: Okay. Very good. Thanks for taking our questions. Congrats on the end market demand.

Dr. Jeffrey Dayno: Yeah. Sure, Charles. And we are very excited about for that topline data readout as well. So obviously, the team is will be working aggressively and focused on producing topline results and we look forward to sharing that with you when they come.

Charles Duncan: Okay. Thank you.

Operator: Thank you. And at this time, I will now turn the call back to management for any additional or closing remarks.

Dr. Jeffrey Dayno: Thank you, Todd. And thanks to everyone for joining our call today and for your interest in Harmony. I would also like to thank the talented team at Harmony Biosciences who I have the pleasure of working with for their efforts every day, to deliver on our mission to develop and commercialize innovative treatments for patients living with rare neurological diseases. As you heard from the team this morning, our business remains strong, Harmony continues to be a growth story and we have conviction in the long-term growth potential of our company. We have built momentum during the first half of 2023 and we are now looking forward to a catalyst rich second half of the year. Thank you and have a great day.

Operator: Thank you. This does conclude today’s Harmony Biosciences second quarter 2023 financial results conference call. You may now disconnect your lines and have a wonderful day.

Follow Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)

Page 8 of 8